Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin

@inproceedings{Toyoda2012SignificanceOA,
  title={Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin},
  author={Hidenori Toyoda and Takashi Kumada and Noritomo Shimada and Koichi Takaguchi and Tatsuya Ide and Michio Sata and Hiroyuki Ginba and Kazuhiro Matsuyama and Namiki Izumi},
  booktitle={BMC infectious diseases},
  year={2012}
}
BACKGROUND The importance of the reduction in hepatitis C virus (HCV) RNA levels 4 and 12 weeks after starting peginterferon (PEG-IFN) and ribavirin combination therapy has been reported to predict a sustained virologic response (SVR) in patients infected with HCV genotype 1. We conducted a multicenter study to validate this importance along with baseline predictive factors in this patient subpopulation. METHODS A total of 516 patients with HCV genotype 1 and pretreatment HCV RNA levels ≥5.0… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 33 references

SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection

  • F Poordad, J JrMcCone, +12 authors JP Bronowicki
  • N Engl J Med
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…